Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…
Where Will Pfizer Be in 5 Years?
Pfizer’s stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live…
Should You Buy Pfizer While It’s Under $30?
Pfizer has been struggling for several years. The company’s pipeline could help it turn things around. It also…
Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong…
How Recent Moves Are Rewriting the Story for Pfizer
Pfizer’s fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate…
Who’s Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Eli Lilly’s GLP-1 drug is now the world’s best-selling drug. Novo Nordisk is struggling with declining market share.…
Why Weight-Loss Drug Prices Are Falling| Business News
President Trump claimed credit Thursday for cutting prices on popular weight-loss drugs by Eli Lilly and Novo Nordisk.…
Trump seeks lower prices for Wegovy, Zepbound
President Donald Trump announces plan to expand IVF access President Donald Trump announced a plan to expand IVF…
5 Things Retirees Need To Know About the New Trump Drug Program
The Trump administration and Pfizer have made an agreement for the drug company to sell many medications to…
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and…
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and…